Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc (A) delivers cutting-edge analytical instruments and laboratory solutions for scientific advancement across biopharmaceutical, diagnostic, and environmental sectors. This page provides investors and industry professionals with a centralized source for all official company announcements and market-relevant developments.
Access real-time updates on Agilent's financial performance, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection includes earnings releases, executive leadership updates, R&D breakthroughs, and industry event coverage—all essential for tracking the company's impact on life sciences and laboratory technology.
Key focus areas include advancements in genomic research tools, sustainability initiatives in lab operations, and cross-sector collaborations driving scientific discovery. Bookmark this page to stay informed about Agilent's evolving role in enabling precision medicine, environmental testing, and next-generation materials analysis.
Helzberg, a Berkshire Hathaway company (NYSE: BRK), released its 2025 Engagement & Ring Shopping Survey revealing key trends in modern proposals and ring shopping behaviors. The study, surveying 1,000 U.S. adults aged 20-40, found that 83% prefer private proposals, despite 88% planning to share ring preferences beforehand.
The survey highlighted significant generational differences, with Gen Z showing stronger engagement in social media research (79% vs. 63% millennials) and sustainability concerns (88% vs. 81%). Notable findings include an average maximum ring budget of $4,000, with 76% willing to invest more for customization. While 83% value in-store purchasing options, 56% consider online buying important, reflecting evolving shopping preferences.
Agilent Technologies (NYSE: A) has launched its new Insight Series Alarm Resolution Systems for airport security screening, featuring the Insight300M and InsightBLS models. These advanced liquid explosive detection systems (LEDs) are designed to screen liquids, aerosols, and gels (LAGs) at airport checkpoints.
The systems boast the industry's lowest false alarm rate and rapid scan times, capable of identifying threats through complex barriers and multi-layered materials. A key feature is their future-proof design, allowing updates through software upgrades without hardware replacement. The launch builds on Agilent's 2017 acquisition of Cobalt Light Systems and will be showcased at the International Security Expo in London.
Agilent Technologies (NYSE: A) has launched the new Altura Ultra Inert HPLC Columns, designed specifically for biotherapeutics applications. The innovative columns demonstrate up to 2x sensitivity and 3x signal-to-noise ratio compared to competitors, while achieving up to 30x higher peak area when used with Agilent's 1290 Infinity III Bio LC.
The Altura line addresses critical needs in biopharma testing, particularly for peptide GLP-1 and oligonucleotide therapeutic development. Early testing shows a 30% increase in sensitivity and reduced peak tailing for acidic peptides and excipients analysis, offering superior chromatographic performance through faster conditioning, improved peak shape, and enhanced sensitivity.
Agilent Technologies (NYSE: A) has announced a nonexclusive collaboration with Lunit (KRX:328130.KQ) to develop AI-powered companion diagnostic solutions. The partnership combines Lunit's artificial intelligence expertise with Agilent's tissue-based diagnostic capabilities to enhance biomarker testing accuracy.
The collaboration will initially focus on developing AI-powered assays for research and clinical trials, integrating Lunit's AI algorithms with Agilent's state-of-the-art assays. The joint solutions aim to support pharmaceutical companies in companion diagnostic product development, potentially accelerating the development of biomarker-driven therapies and improving patient treatment precision.
Agilent Technologies (NYSE: A) has declared a quarterly dividend of 24.8 cents per share of common stock. The dividend will be paid on October 22, 2025, to shareholders of record as of September 30, 2025. Future dividend payments remain subject to board approval.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Bank of America Global Healthcare Conference in London. The presentation is scheduled for September 25, 2025, from 9:50-10:30 AM BST. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has achieved the highest level of My Green Lab Certification—Green level—at its Refurbishment Centers in Delaware, USA, and Singapore. The centers scored 90% and 87% respectively in rigorous sustainability assessments across 12 critical categories.
The certification highlights Agilent's Certified Pre-Owned (CPO) program, which restores used instruments to factory-grade condition, supporting a circular lab economy through trade-in and buy-back options. Approximately 50% of refurbishment team members have become My Green Lab Ambassadors, demonstrating the company's commitment to sustainability.
TORM plc (NASDAQ: TRMD) announced that Hafnia Limited will acquire approximately 14.1 million A shares (14.45% of TORM's issued share capital) from Oaktree Capital Management. The transaction is valued at USD 22 per share, totaling USD 311.4 million.
The share purchase completion is subject to several conditions, including regulatory approvals, satisfaction of certain covenants, and the appointment of a new independent board chairman. TORM clarified that it was not involved in the transaction and has no additional information at this time.
Agilent Technologies (NYSE: A) announced its participation as a premium sponsor at the European Congress of Pathology (ECP) 2025 in Vienna, Austria, from September 6-10, 2025. The company will showcase the European launch of its expanded Dako Omnis Family of instruments, including the Dako Omnis 110, 165, and 165 Duo models.
The event will feature live demonstrations, expert sessions, and educational symposia focusing on diagnostic excellence and workflow optimization. Visitors can explore Agilent's Digital Pathology solutions and participate in PD-L1 CPS scoring sessions at booth #18.
Agilent Technologies (NYSE: A) has achieved a significant regulatory milestone as its MMR IHC Panel pharmDx (Dako Omnis) received European IVDR certification as a class C companion diagnostic test for colorectal cancer. The panel is specifically designed to identify mismatch repair (MMR) deficient CRC patients who may be eligible for treatment with OPDIVO® in combination with YERVOY®.
The diagnostic panel is uniquely positioned as the only companion diagnostic IHC panel IVDR approved for this specific treatment combination in colorectal cancer patients. The test works by detecting the loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in tissue samples, helping identify patients who may respond better to immunotherapy.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
